Interaksi Hidroklorotiazid

Hidroklorotiazid (Microzide, HydroDiuril), golongan diuretik tiazid, memiliki 354 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 36 mayor, 274 moderat, 42 minor, dan 2 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (36)

  • Amiloriddiuretik hemat kaliumMayor

    Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. (label Amilorid, Peringatan kotak hitam)

  • Arsen trioksidaobat yang memperpanjang interval QTMayor

    The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (label Arsen trioksida, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopMayor

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (label Asam etakrinat, Kontraindikasi)

  • Asetazolamidpenghambat karbonat anhidraseMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (label Benazepril dan hidroklorotiazid, Kontraindikasi)

  • Brinzolamidpenghambat karbonat anhidraseMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • Bumetaniddiuretik loopMayor

    WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (label Bumetanid, Peringatan kotak hitam)

  • CONTRAINDICATIONS PROGLYCEM is contraindicated in patients with: Functional hypoglycemia Hypersensitivity to diazoxide, any of the excipients in PROGLYCEM, or other thiazides (label Diazoksid, Kontraindikasi)

  • Diklorfenamidpenghambat karbonat anhidraseMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • DofetilidantiaritmiaMayor

    The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with dofetilide is contraindicated (see PRECAUTIONS, Drug-Drug Interactions ) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation. (label Dofetilid, Kontraindikasi)

  • Dorzolamidpenghambat karbonat anhidraseMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • Dorzolamid dan timololpenghambat karbonat anhidraseMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • Droperidolantagonis dopaminMayor

    Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (label Droperidol, Peringatan kotak hitam)

  • Enalaprilatpenghambat ACEMayor

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Enalaprilat, Peringatan)

  • Eplerenonantagonis aldosteronMayor

    …• serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions (7) , and Clinical Pharmacology (12.3)… (label Eplerenon, Kontraindikasi)

  • EptifibatidantiplateletMayor

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (label Eptifibatid, Kontraindikasi)

  • Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (label Folitropin, Peringatan dan perhatian)

  • GentamisinaminoglikosidaMayor

    The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (label Gentamisin, Peringatan kotak hitam)

  • Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

  • Itrakonazolantijamur azolMayor

    Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (label Itrakonazol, Interaksi obat)

  • Kalium sitratsuplemen kaliumMayor

    The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (label Kalium sitrat, Interaksi obat)

  • KlozapinantipsikotikMayor

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (label Klozapin, Peringatan kotak hitam)

  • Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (label Koriogonadotropin alfa, Peringatan)

  • Kuinaprilpenghambat ACEMayor

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Kuinapril, Peringatan)

  • Metazolamidpenghambat karbonat anhidraseMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • Metolazondiuretik tiazidMayor

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (label Metolazon, Peringatan)

  • MinoksidilvasodilatorMayor

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (label Minoksidil, Peringatan kotak hitam)

  • Natrium bikarbonatantasidaMayor

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (label Natrium bikarbonat, Kontraindikasi)

  • NeomisinaminoglikosidaMayor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (label Neomisin, Peringatan kotak hitam)

  • Perak sulfadiazinsulfonamidaMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • SiklosporinimunosupresanMayor

    Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (label Siklosporin, Interaksi obat)

  • SulfadiazinsulfonamidaMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • SulfasalazinsulfonamidaMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

  • Tadalafilpenghambat PDE5Mayor

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (label Tadalafil, Peringatan dan perhatian)

  • ZonisamidantikonvulsanMayor

    In patients with hypersensitivity to sulfonamide-derived drugs. (label Hidroklorotiazid, Kontraindikasi)

Interaksi moderat (274)

  • AkarbosaantidiabetesModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Alfuzosinpenyekat alfaModerat

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (label Alfuzosin, Peringatan dan perhatian)

  • AliskirenantihipertensiModerat

    Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (label Aliskiren, Peringatan dan perhatian)

  • Alogliptinpenghambat DPP-4Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Alopurinolpenghambat xantin oksidaseModerat

    Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (label Alopurinol, Peringatan dan perhatian)

  • AmikasinaminoglikosidaModerat

    Ethacrynic Acid, Furosemide, Urea, or Mannitol Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. (label Amikasin, Interaksi obat)

  • AmiodaronantiaritmiaModerat

    Give special attention to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics and laxatives. (label Amiodaron, Peringatan dan perhatian)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (label Amlodipin dan benazepril, Peringatan dan perhatian)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    In patients with an activated renin-angiotensin system, such as volume and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil . (label Amlodipin dan olmesartan, Peringatan dan perhatian)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur in patients receiving angiotensin receptor blockers. (label Amlodipin dan valsartan, Peringatan dan perhatian)

  • Amoksisilinantibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • Amoksisilin dan klavulanatantibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • Ampisilinantibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • Ampisilin dan sulbaktamantibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • Arformoterolagonis beta-adrenergikModerat

    Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (label Arformoterol, Interaksi obat)

  • AripiprazolantipsikotikModerat

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (label Aripiprazol, Interaksi obat)

  • Armodafinilstimulan SSPModerat

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (label Armodafinil, Peringatan dan perhatian)

  • Asam mefenamatOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Asam zoledronatbisfosfonatModerat

    Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (label Asam zoledronat, Peringatan dan perhatian)

  • Asebutololpenyekat betaModerat

    Although β-blockers should be avoided in overt cardiac failure, acebutolol can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. (label Asebutolol, Peringatan)

  • AsenapinantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (label Asenapin, Peringatan dan perhatian)

  • AspirinOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Aspirin dan dipiridamolantiplateletModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Atenololpenyekat betaModerat

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (label Atenolol, Peringatan)

  • Atenolol dan klortalidonpenyekat betaModerat

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (label Atenolol dan klortalidon, Peringatan)

  • Atomoksetinpenghambat ambilan kembali norepinefrinModerat

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (label Atomoksetin, Interaksi obat)

  • Avanafilpenghambat PDE5Moderat

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (label Avanafil, Peringatan dan perhatian)

  • Azilsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with azilsartan medoxomil. (label Azilsartan, Peringatan dan perhatian)

  • Beksagliflozinpenghambat SGLT2Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Beladona dan opiumopioidModerat

    Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Beladona dan opium, Interaksi obat)

  • Benazeprilpenghambat ACEModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Benazepril, Peringatan dan perhatian)

  • Benzfetaminstimulan SSPModerat

    Amphetamines may decrease the hypotensive effect of antihypertensives. (label Benzfetamin, Interaksi obat)

  • Benzilpenisilin (penisilin G)antibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • Bisoprololpenyekat betaModerat

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (label Bisoprolol, Peringatan)

  • Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (label Bisoprolol dan hidroklorotiazid, Peringatan)

  • BortezomibModerat

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (label Bortezomib, Peringatan dan perhatian)

  • BrekspiprazolantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Brekspiprazol, Peringatan dan perhatian)

  • Brimonidinagonis alfa-adrenergikModerat

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (label Brimonidin, Interaksi obat)

  • Brimonidin dan timololagonis alfa-adrenergikModerat

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (label Brimonidin dan timolol, Interaksi obat)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (label Bromfeniramin, pseudoefedrin, dan dekstrometorfan, Interaksi obat)

  • Bromokriptinagonis dopaminModerat

    Use caution in patients taking antihypertensive medications. (label Bromokriptin, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    Diuretics: Use with caution. (label Budesonid dan formoterol, Interaksi obat)

  • BuprenorfinopioidModerat

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Buprenorfin, Interaksi obat)

  • Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Buprenorfin dan nalokson, Interaksi obat)

  • NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Butalbital, parasetamol, kafein, dan kodein, Interaksi obat)

  • Dapagliflozinpenghambat SGLT2Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Dekslansoprazolpenghambat pompa protonModerat

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (label Dekslansoprazol, Peringatan dan perhatian)

  • Deksmetilfenidatstimulan SSPModerat

    • Antihypertensive Drugs: Monitor blood pressure. (label Deksmetilfenidat, Interaksi obat)

  • Desipraminantidepresan trisiklikModerat

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (label Desipramin, Peringatan)

  • …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (label Desmopresin, Interaksi obat)

  • DesvenlafaksinSNRIModerat

    Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (label Desvenlafaksin, Peringatan dan perhatian)

  • Dietilpropionstimulan SSPModerat

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (label Dietilpropion, Interaksi obat)

  • DiflunisalOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Digoksinglikosida digitalisModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • DiklofenakOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Dikloksasilinantibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • Dokserkalsiferolanalog vitamin DModerat

    Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (label Dokserkalsiferol, Peringatan dan perhatian)

  • Drospirenon dan etinilestradiolkontrasepsi oralModerat

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (label Drospirenon dan etinilestradiol, Peringatan dan perhatian)

  • Dulaglutidagonis reseptor GLP-1Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • DuloksetinSNRIModerat

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (label Duloksetin, Peringatan dan perhatian)

  • Eksenatidagonis reseptor GLP-1Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Empagliflozinpenghambat SGLT2Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Enalaprilpenghambat ACEModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Enalapril, Peringatan dan perhatian)

  • EpinefrinsimpatomimetikModerat

    …Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline… (label Epinefrin, Interaksi obat)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (label Epoetin alfa, Peringatan dan perhatian)

  • Epoprostenolanalog prostaglandinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • EsitalopramSSRIModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Esmololpenyekat betaModerat

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (label Esmolol, Interaksi obat)

  • Esomeprazolpenghambat pompa protonModerat

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (label Esomeprazol, Peringatan dan perhatian)

  • EtodolakOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Fenelzinpenghambat MAOModerat

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (label Fenelzin, Peringatan)

  • Fenoksimetilpenisilin (penisilin V)antibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • FenoprofenOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • FentanilopioidModerat

    …treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (label Fentanil, Peringatan dan perhatian)

  • Fentermin dan topiramatstimulan SSPModerat

    Concomitant administration of hydrochlorothiazide alone with topiramate alone has been shown to increase the C max and AUC of topiramate by 27% and 29%, respectively. (label Fentermin dan topiramat, Interaksi obat)

  • FludrokortisonkortikosteroidModerat

    Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (label Fludrokortison, Interaksi obat)

  • Flukonazolantijamur azolModerat

    Hydrochlorothiazide In a pharmacokinetic interaction study, coadministration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentrations of fluconazole by 40%. (label Flukonazol, Interaksi obat)

  • FluoksetinSSRIModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Fluoksetin, Peringatan dan perhatian)

  • FlurbiprofenOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Flutikason dan salmeterolkortikosteroidModerat

    Diuretics: Use with caution. (label Flutikason dan salmeterol, Interaksi obat)

  • FluvoksaminSSRIModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Fluvoksamin, Peringatan dan perhatian)

  • Formoterolagonis beta-adrenergikModerat

    • Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (label Formoterol, Interaksi obat)

  • Fosinoprilpenghambat ACEModerat

    In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propranolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs. (label Fosinopril, Interaksi obat)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    The thiazide component of fosinopril sodium and hydrochlorothiazide may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. (label Fosinopril dan hidroklorotiazid, Peringatan)

  • FoskarnetantivirusModerat

    When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (label Foskarnet, Interaksi obat)

  • Furosemiddiuretik loopModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • GlibenklamidsulfonilureaModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Glibenklamid dan metforminsulfonilureaModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • GlimepiridsulfonilureaModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • GlipizidsulfonilureaModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Glipizid dan metforminsulfonilureaModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • HaloperidolantipsikotikModerat

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (label Haloperidol, Interaksi obat)

  • HidrokodonopioidModerat

    Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Hidrokodon, Interaksi obat)

  • Diuretics : Hydrocodone may reduce the efficacy of diuretics. (label Hidrokodon dan homatropin, Interaksi obat)

  • NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Diuretics : Hydrocodone may reduce the efficacy of diuretics. (label Hidrokodon dan klorfeniramin, Interaksi obat)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Hidrokodon dan parasetamol, Interaksi obat)

  • HidromorfonopioidModerat

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Hidromorfon, Interaksi obat)

  • IbuprofenOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • IloperidonantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Iloperidon, Peringatan dan perhatian)

  • Imipraminantidepresan trisiklikModerat

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (label Imipramin, Peringatan)

  • Indapamiddiuretik tiazidModerat

    Drug Interactions Other Antihypertensives: Indapamide may add to or potentiate the action of other antihypertensive drugs. (label Indapamid, Interaksi obat)

  • IndometasinOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Insulin aspartinsulinModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Insulin degludekinsulinModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Insulin detemirinsulinModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Insulin glargininsulinModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Insulin lisproinsulinModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Ipratropium dan salbutamolantikolinergikModerat

    Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (label Ipratropium dan salbutamol, Interaksi obat)

  • Irbesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with AVAPRO. (label Irbesartan, Peringatan dan perhatian)

  • Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (label Kalium iodida, Interaksi obat)

  • Kalsitriolanalog vitamin DModerat

    Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. (label Kalsitriol, Interaksi obat)

  • Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (label Kalsium klorida, Interaksi obat)

  • Kanagliflozinpenghambat SGLT2Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Kandesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (label Kandesartan, Peringatan dan perhatian)

  • Kaptoprilpenghambat ACEModerat

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (label Kaptopril, Peringatan)

  • KarbamazepinantikonvulsanModerat

    Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (label Karbamazepin, Peringatan dan perhatian)

  • KarbidopaModerat

    Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (label Karbidopa, Interaksi obat)

  • Karbidopa dan levodopaobat dopaminergikModerat

    Antihypertensive drugs: May cause symptomatic postural hypotension. (label Karbidopa dan levodopa, Interaksi obat)

  • Karbidopa, levodopa, dan entakaponobat dopaminergikModerat

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (label Karbidopa, levodopa, dan entakapon, Interaksi obat)

  • KariprazinantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Kariprazin, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (label Karvedilol, Peringatan dan perhatian)

  • Ketokonazolantijamur azolModerat

    Diuretics eplerenone The potential increase in plasma concentrations of eplerenone when coadministered with ketoconazole tablets may increase the risk of hyperkalemia and hypotension. (label Ketokonazol, Interaksi obat)

  • KetoprofenOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • KetorolakOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • KlofarabinantimetabolitModerat

    Consider use of diuretics and/or albumin. (label Klofarabin, Peringatan dan perhatian)

  • Klorotiaziddiuretik tiazidModerat

    Thiazides may add to or potentiate the action of other antihypertensive drugs. (label Klorotiazid, Peringatan)

  • KlorpromazinantipsikotikModerat

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (label Klorpromazin, Perhatian)

  • Klortalidondiuretik tiazidModerat

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (label Klortalidon, Interaksi obat)

  • KodeinopioidModerat

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Kodein, Interaksi obat)

  • Kolestipolsekuestran asam empeduModerat

    Cholestyramine and colestipol: Reduced absorption of thiazides (7.1) (label Hidroklorotiazid, Interaksi obat)

  • Kolestiraminsekuestran asam empeduModerat

    Cholestyramine and colestipol: Reduced absorption of thiazides (7.1) (label Hidroklorotiazid, Interaksi obat)

  • KuetiapinantipsikotikModerat

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Kuetiapin, Peringatan dan perhatian)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    The thiazide component of quinapril and hydrochlorothiazide tablets may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic- blocking drugs. (label Kuinapril dan hidroklorotiazid, Peringatan)

  • KuinidinantiaritmiaModerat

    Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine. (label Kuinidin, Interaksi obat)

  • Lansoprazolpenghambat pompa protonModerat

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (label Lansoprazol, Peringatan dan perhatian)

  • LevomilnasipranSNRIModerat

    Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (label Levomilnasipran, Peringatan dan perhatian)

  • LevorfanolopioidModerat

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Levorfanol, Interaksi obat)

  • Levosalbutamolagonis beta-adrenergikModerat

    Diuretics The ECG changes or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (label Levosalbutamol, Interaksi obat)

  • Linagliptinpenghambat DPP-4Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • LinezolidantibiotikModerat

    Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (label Linezolid, Peringatan dan perhatian)

  • Liraglutidagonis reseptor GLP-1Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Lisinoprilpenghambat ACEModerat

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Lisinopril, Peringatan dan perhatian)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed (see DOSAGE AND ADMINISTRATION ). (label Lisinopril dan hidroklorotiazid, Interaksi obat)

  • Litiumobat serotonergikModerat

    Lithium: Increased lithium concentrations and lithium toxicity (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Losartanpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • LumateperonantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (label Lumateperon, Peringatan dan perhatian)

  • LurasidonantipsikotikModerat

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (label Lurasidon, Peringatan dan perhatian)

  • MekamilaminantihipertensiModerat

    The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (label Mekamilamin, Interaksi obat)

  • MeloksikamOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • MetadonopioidModerat

    Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (label Metadon, Peringatan dan perhatian)

  • MetforminbiguanidModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Metilfenidatstimulan SSPModerat

    Antihypertensive Drugs: Monitor blood pressure. (label Metilfenidat, Interaksi obat)

  • Metoprololpenyekat betaModerat

    If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of Metoprolol Tartrate Tablets [see Dosage and Administration (2) ]. (label Metoprolol, Peringatan dan perhatian)

  • MiglitolantidiabetesModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • MilnasipranSNRIModerat

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (label Milnasipran, Peringatan dan perhatian)

  • MirtazapinantidepresanModerat

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (label Mirtazapin, Peringatan dan perhatian)

  • Modafinilstimulan SSPModerat

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (label Modafinil, Peringatan dan perhatian)

  • Moeksiprilpenghambat ACEModerat

    Symptomatic hypotension is most likely to occur in patients who have been salt- and volume- depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (label Moeksipril, Peringatan)

  • MorfinopioidModerat

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Morfin, Interaksi obat)

  • NabumetonOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Nadololpenyekat betaModerat

    Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (label Nadolol, Peringatan)

  • Nafsilinantibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • NalbufinopioidModerat

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Nalbufin, Interaksi obat)

  • NaproksenOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • NateglinidmeglitinidModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (label Natrium zirkonium siklosilikat, Peringatan dan perhatian)

  • NiasinModerat

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (label Niasin, Interaksi obat)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    Other Diuretics, PDE5 inhibitors, alpha-methyldopa: Nifedipine may increase the blood pressure lowering effect of these concomitantly administered agents. (label Nifedipin, Interaksi obat)

  • Nimodipinpenghambat kanal kalsium dihidropiridinModerat

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (label Nimodipin, Interaksi obat)

  • NitrogliserinnitratModerat

    Antihypertensives: Possible additive hypotensive effects. (label Nitrogliserin, Interaksi obat)

  • OksaprozinOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Oksasilinantibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • OksikodonopioidModerat

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Oksikodon, Interaksi obat)

  • Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Oksikodon dan parasetamol, Interaksi obat)

  • OksimorfonopioidModerat

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Oksimorfon, Interaksi obat)

  • OlanzapinantipsikotikModerat

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (label Olanzapin, Peringatan dan perhatian)

  • Olanzapin dan fluoksetinantipsikotikModerat

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Olanzapin dan fluoksetin, Peringatan dan perhatian)

  • OliseridinopioidModerat

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Oliseridin, Interaksi obat)

  • Olmesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin-aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Benicar. (label Olmesartan, Peringatan dan perhatian)

  • Omeprazolpenghambat pompa protonModerat

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (label Omeprazol, Peringatan dan perhatian)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonModerat

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (label Omeprazol dan natrium bikarbonat, Peringatan dan perhatian)

  • NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • PaliperidonantipsikotikModerat

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (label Paliperidon, Peringatan dan perhatian)

  • Pantoprazolpenghambat pompa protonModerat

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (label Pantoprazol, Peringatan dan perhatian)

  • NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Parasetamol dan kodein, Interaksi obat)

  • Parikalsitolanalog vitamin DModerat

    The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (label Parikalsitol, Peringatan dan perhatian)

  • ParoksetinSSRIModerat

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (label Paroksetin, Peringatan dan perhatian)

  • PazopanibModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Pentazosin dan nalokson, Interaksi obat)

  • PentoksifilinmetilxantinModerat

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (label Pentoksifilin, Interaksi obat)

  • Perindoprilpenghambat ACEModerat

    Symptomatic hypotension is most likely to occur in patients who have been volume or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting [see Dosage and Administration (2.1) ] . (label Perindopril, Peringatan dan perhatian)

  • PetidinopioidModerat

    Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Petidin, Interaksi obat)

  • Pindololpenyekat betaModerat

    Although beta-blockers should be avoided in overt congestive heart failure, if necessary, pindolol tablets can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (label Pindolol, Peringatan)

  • PioglitazontiazolidindionModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Pioglitazon dan metformintiazolidindionModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Piperasilin dan tazobaktamantibiotik penisilinModerat

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Hidroklorotiazid, Peringatan dan perhatian)

  • PiroksikamOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Prazosinpenyekat alfaModerat

    Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (label Prazosin, Peringatan)

  • ProklorperazinantipsikotikModerat

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (label Proklorperazin, Perhatian)

  • Diuretics : Codeine may reduce the efficacy of diuretics. (label Prometazin dan kodein, Interaksi obat)

  • Rabeprazolpenghambat pompa protonModerat

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (label Rabeprazol, Peringatan dan perhatian)

  • Ramiprilpenghambat ACEModerat

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (label Ramipril, Peringatan dan perhatian)

  • RepaglinidmeglitinidModerat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • RiosiguatvasodilatorModerat

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (label Riosiguat, Peringatan dan perhatian)

  • RisperidonantipsikotikModerat

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (label Risperidon, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Sakubitril dan valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. (label Sakubitril dan valsartan, Peringatan dan perhatian)

  • Salbutamolagonis beta-adrenergikModerat

    Diuretics: Use with caution. (label Salbutamol, Interaksi obat)

  • Salmeterolagonis beta-adrenergikModerat

    • Diuretics: Use with caution. (label Salmeterol, Interaksi obat)

  • SalsalatOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • SefepimsefalosporinModerat

    Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (label Sefepim, Interaksi obat)

  • SeftazidimsefalosporinModerat

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (label Seftazidim, Interaksi obat)

  • SelekoksibOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Semaglutidagonis reseptor GLP-1Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • SertralinSSRIModerat

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (label Sertralin, Peringatan dan perhatian)

  • Siklobenzaprinpelemas ototModerat

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (label Siklobenzaprin, Interaksi obat)

  • SiklofosfamidimunosupresanModerat

    …inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity… (label Siklofosfamid, Interaksi obat)

  • Sildenafilpenghambat PDE5Moderat

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (label Sildenafil, Peringatan dan perhatian)

  • Silodosinpenyekat alfaModerat

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (label Silodosin, Peringatan dan perhatian)

  • Sitagliptinpenghambat DPP-4Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • SitalopramSSRIModerat

    Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (label Sitalopram, Peringatan dan perhatian)

  • SorafenibModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Sotalolpenyekat betaModerat

    Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (label Sotalol, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Suksinilkolinpenyekat neuromuskularModerat

    Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (label Suksinilkolin, Peringatan dan perhatian)

  • SulindakOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • SunitinibModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • TakrolimusimunosupresanModerat

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (label Takrolimus, Peringatan dan perhatian)

  • TapentadolopioidModerat

    …use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Tapentadol, Interaksi obat)

  • Telmisartanpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan tablets. (label Telmisartan, Peringatan dan perhatian)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (label Telmisartan dan amlodipin, Peringatan dan perhatian)

  • Terazosinpenyekat alfaModerat

    Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (label Terazosin, Peringatan dan perhatian)

  • Terbutalinagonis beta-adrenergikModerat

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (label Terbutalin, Perhatian)

  • TestosteronandrogenModerat

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (label Testosteron, Peringatan dan perhatian)

  • Tirzepatidagonis reseptor GLP-1Moderat

    Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

  • TobramisinaminoglikosidaModerat

    Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

  • TolmetinOAINSModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • TolvaptanModerat

    Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (label Tolvaptan, Peringatan dan perhatian)

  • TopiramatantikonvulsanModerat

    Hydrochlorothiazide (HCTZ) Topiramate C max and AUC increased when HCTZ was added to immediate-release topiramate. (label Topiramat, Interaksi obat)

  • Torasemiddiuretik loopModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Toremifenmodulator reseptor estrogen selektifModerat

    Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (label Toremifen, Interaksi obat)

  • TramadolopioidModerat

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Tramadol, Interaksi obat)

  • Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Tramadol dan parasetamol, Interaksi obat)

  • Trandolaprilpenghambat ACEModerat

    Symptomatic hypotension is most likely to occur in patients who have been salt- or volume-depleted as a result of prolonged treatment with diuretics, dietary salt restriction, dialysis, diarrhea, or vomiting. (label Trandolapril, Peringatan)

  • TrazodonantidepresanModerat

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (label Trazodon, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    NSAID: May lead to increased risk of renal impairment and loss of diuretic and antihypertensive effect (7.1). (label Hidroklorotiazid, Interaksi obat)

  • TrifluoperazinantipsikotikModerat

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (label Trifluoperazin, Perhatian)

  • Umeklidinium dan vilanterolantikolinergikModerat

    • Diuretics: Use with caution. (label Umeklidinium dan vilanterol, Interaksi obat)

  • Valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. (label Valsartan, Peringatan dan perhatian)

  • Vardenafilpenghambat PDE5Moderat

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (label Vardenafil, Interaksi obat)

  • VenlafaksinSNRIModerat

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

  • Verapamilpenghambat kanal kalsiumModerat

    Control patients with milder ventricular dysfunction, if possible, with optimum doses of digitalis and/or diuretics before verapamil treatment is started [see Drug Interactions ( 7.5 )] . (label Verapamil, Peringatan dan perhatian)

  • VilazodonSSRIModerat

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (label Vilazodon, Peringatan dan perhatian)

  • Vitamin DVitamin dan mineralModerat

    Diuretik tiazid mengurangi ekskresi kalsium; bila dikombinasikan dengan suplemen vitamin D dan kalsium, hal ini dapat berujung pada hiperkalsemia, terutama pada orang lanjut usia. (NIH Office of Dietary Supplements, Vitamin D)

  • VortioksetinantidepresanModerat

    Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (label Vortioksetin, Peringatan dan perhatian)

  • ZiprasidonantipsikotikModerat

    Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (label Ziprasidon, Peringatan dan perhatian)

Penyebutan minor (42)

  • AmantadinantikolinergikMinor

    Coadministration of 1 Dyazide (triamterene/hydrochlorothiazide) resulted in a higher plasma amantadine hydrochloride concentration in a 61-year old man receiving amantadine hydrochloride 100 mg TID for Parkinson's disease. (label Amantadin, Interaksi obat)

  • Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (label Ambrisentan, Peringatan dan perhatian)

  • Betaksololpenyekat betaMinor

    Drug Interactions The following drugs have been coadministered with betaxolol and have not altered its pharmacokinetics: cimetidine, nifedipine, chlorthalidone, and hydrochlorothiazide. (label Betaksolol, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Minor

    Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (label Bosentan, Peringatan dan perhatian)

  • ButorfanolopioidMinor

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (label Butorfanol, Peringatan)

  • Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Dekstroamfetaminstimulan SSPMinor

    Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g., sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides). (label Dekstroamfetamin, Interaksi obat)

  • Desogestrel dan etinilestradiolkontrasepsi oralMinor

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (label Desogestrel dan etinilestradiol, Peringatan)

  • Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

  • DronedaronantiaritmiaMinor

    Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. (label Dronedaron, Peringatan dan perhatian)

  • EfedrinsimpatomimetikMinor

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (label Efedrin, Interaksi obat)

  • Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (label Enalapril dan hidroklorotiazid, Peringatan)

  • In addition to discontinuation of the drug, diuretic therapy may be required. (label Estrogen teresterifikasi dan metiltestosteron, Peringatan)

  • Febuksostatpenghambat xantin oksidaseMinor

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (label Febuksostat, Interaksi obat)

  • Finasteridpenghambat 5-alfa reduktaseMinor

    …clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (label Finasterid, Interaksi obat)

  • FlekainidantiaritmiaMinor

    Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (label Flekainid, Interaksi obat)

  • HidralazinvasodilatorMinor

    When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (label Hidralazin, Interaksi obat)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (label Ikatibant, Interaksi obat)

  • Imatinibpenghambat CYP3A4Minor

    Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (label Imatinib, Peringatan dan perhatian)

  • Isradipinpenghambat kanal kalsium dihidropiridinMinor

    Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of isradipine and hydrochlorothiazide does not result in altered pharmacokinetics of either drug. (label Isradipin, Interaksi obat)

  • KaliumVitamin dan mineralMinor

    Diuretik loop dan diuretik tiazid meningkatkan kehilangan kalium; suplementasi kadang diresepkan bersamanya. (NIH Office of Dietary Supplements, Potassium)

  • KalsiumVitamin dan mineralMinor

    Diuretik tiazid mengurangi ekskresi kalsium, sehingga asupan kalsium yang tinggi dapat menaikkan kalsium darah. (NIH Office of Dietary Supplements, Calcium)

  • Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (label Kalsium glukonat, Interaksi obat)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (label Kandesartan dan hidroklorotiazid, Peringatan)

  • Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (label Kortikotropin, Interaksi obat)

  • MagnesiumVitamin dan mineralMinor

    Penggunaan jangka panjang diuretik loop dan diuretik tiazid meningkatkan kehilangan magnesium melalui urine. (NIH Office of Dietary Supplements, Magnesium)

  • Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • MeksiletinantiaritmiaMinor

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (label Meksiletin, Interaksi obat)

  • MetildopaantihipertensiMinor

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (label Metildopa, Interaksi obat)

  • MetilprednisolonkortikosteroidMinor

    Amphotericin B injection and potassium-depleting agents : When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (label Metilprednisolon, Interaksi obat)

  • MetiltestosteronandrogenMinor

    In addition to discontinuation of the drug, diuretic therapy may be required. (label Metiltestosteron, Peringatan)

  • Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (label Metoprolol dan hidroklorotiazid, Peringatan dan perhatian)

  • Milrinonpenghambat PDE3Minor

    …been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (label Milrinon, Interaksi obat)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinMinor

    The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (label Nisoldipin, Interaksi obat)

  • NitroprusidvasodilatorMinor

    Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (label Nitroprusid, Peringatan)

  • Nortriptilinantidepresan trisiklikMinor

    The antihypertensive action of guanethidine and similar agents may be blocked. (label Nortriptilin, Peringatan)

  • PrednisolonkortikosteroidMinor

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednisolon, Interaksi obat)

  • PrednisonkortikosteroidMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Protriptilinantidepresan trisiklikMinor

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (label Protriptilin, Peringatan)

  • TerbinafinantijamurMinor

    There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (label Terbinafin, Interaksi obat)

  • TriamsinolonkortikosteroidMinor

    Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents ( i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (label Triamsinolon, Interaksi obat)

  • Zink (seng)Vitamin dan mineralMinor

    Diuretik tiazid meningkatkan kehilangan zink melalui urine pada penggunaan jangka panjang. (NIH Office of Dietary Supplements, Zinc)

Tidak ada interaksi bermakna yang dilaporkan (2)

  • PamidronatbisfosfonatTanpa interaksi

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (label Pamidronat, Interaksi obat)

  • Ropinirolagonis dopaminTanpa interaksi

    Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (label Ropinirol, Interaksi obat)

Periksa Hidroklorotiazid terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.